@article{53471ba897384625a18eabfb6a6dc4ab,
title = "Empagliflozin in acute myocardial infarction: the EMMY trial.",
keywords = "NATRIURETIC PEPTIDE, EJECTION FRACTION, HEART-FAILURE, NEPRILYSIN INHIBITION, CLINICAL-OUTCOMES, SGLT2 INHIBITORS, PROGNOSTIC VALUE, FOLLOW-UP, ASSOCIATION, RECOVERY",
author = "{von Lewinski}, Dirk and Ewald Kolesnik and Tripolt, {Norbert J} and Pferschy, {Peter N} and Martin Benedikt and Markus Wallner and Hannes Alber and Rudolf Berger and Michael Lichtenauer and Saely, {Christoph H} and Deddo Moertl and Pia Auersperg and Christian Reiter and Thomas Rieder and Siller-Matula, {Jolanta M} and Gager, {Gloria M} and Matthias Hasun and Franz Weidinger and Pieber, {Thomas R} and Zechner, {Peter M} and Markus Herrmann and Andreas Zirlik and Holman, {Rury R} and Abderrahim Oulhaj and Harald Sourij",
note = "Lichtenauer: Paracelsus Med Private Univ Salzburg, Dept Internal Med 2, Div Cardiol & Internal Intens Care Med, Salzburg, Austria",
year = "2022",
doi = "10.1093/eurheartj/ehac494",
language = "English",
volume = "43",
pages = "4421--4432",
journal = "EUROPEAN HEART JOURNAL ",
issn = "0195-668X",
publisher = "Oxford Univ Press",
number = "41",
}